https://www.prnewswire.com/news-releases/esperare-erhalt-breakthrough-therapy-designation-fur-vorgeburtlichen-therapieansatz-mit-er-004-bei-x-chromosomaler-hypohidrotischer-ektodermaler-dysplasie-xlhed--885603485.html
https://www.prnewswire.com/news-releases/esperare-recoit-de-la-fda-la-designation-breakthrough-therapy-pour-er-004-son-traitement-candidate-pour-la-dysplasie-ectodermique-hypohidrotique-liee-a-l-x-xlhed--853073085.html